PhD, Vice President of Research and Development
Dr. Lyle joined the company in 2006 as a medicinal chemist working on our early stage drug development programs in inflammatory diseases and cancer. From there he became the Head of Chemistry in 2008 and the VP of Research and Development in 2010. Dr. Lyle played an integral role in the development of WBI1001 and these efforts ultimately culminated in the $230M acquisition of WBI1001 by GSK in July 2012. Dr. Lyle holds a PhD in Chemistry from Simon Fraser University (SFU) and has authored numerous peer-reviewed scientific publications and patents.